US6426342B2
(en)
*
|
1999-08-16 |
2002-07-30 |
Revaax Pharmaceuticals, Llc |
Use of β-lactamase inhibitors as neuroprotectants
|
BR0013366A
(en)
*
|
1999-08-16 |
2002-07-23 |
Revaax Pharmaceuticals Llc |
Methods to treat a behavioral disorder, a human patient, prostate disease, anxiety and cognitive disorders in a human patient afflicted with a condition or willing to develop a condition distinguished at least in part by the concentration of abnormal extracellular glutamate in the brain or in other nervous tissue, behavioral disorder in human, canine, feline and equine species and a patient afflicted with or willing to develop a disease comprising abnormally high glutamate concentrations in neuronal tissue or elevated naaladase levels in prostate tissue and with multiple sclerosis and to enhance cognitive function, pharmaceutical formulation and uses of an inhibitor of peptidase activity of an acidic dipeptidase bound in n-acetylated alpha and a beta-lactam compound
|
MXPA02009587A
(en)
*
|
2000-03-28 |
2003-05-14 |
Biochemie Gmbh |
Granulated particles with masked taste.
|
US20040062757A1
(en)
*
|
2001-06-05 |
2004-04-01 |
Finegold Sydney M. |
Method of testing gastrointestinal diseases associated with species of genus clostridium
|
AUPQ899700A0
(en)
|
2000-07-25 |
2000-08-17 |
Borody, Thomas Julius |
Probiotic recolonisation therapy
|
US20060121488A1
(en)
*
|
2003-02-26 |
2006-06-08 |
Rothstein Jeffrey D |
Glutamate transport modulatory compounds and methods
|
US20040265279A1
(en)
*
|
2003-05-08 |
2004-12-30 |
Timothy Dinan |
Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
|
US7749509B2
(en)
*
|
2003-08-29 |
2010-07-06 |
Cobb And Company, Llp |
Treatment of autism using probiotic composition
|
US8192733B2
(en)
*
|
2003-08-29 |
2012-06-05 |
Cobb & Associates |
Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
|
US7731976B2
(en)
*
|
2003-08-29 |
2010-06-08 |
Cobb And Company, Llp |
Treatment of irritable bowel syndrome using probiotic composition
|
US7759105B2
(en)
*
|
2003-08-29 |
2010-07-20 |
Cobb & Company, Llp |
Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
|
JP2007505095A
(en)
*
|
2003-09-12 |
2007-03-08 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
Combinations comprising alpha-2-delta ligand and SSRI and / or SNRI for the treatment of depression and anxiety disorders
|
US20070238717A1
(en)
*
|
2003-10-21 |
2007-10-11 |
Johns Hopkins University |
Neuroprotection with Beta-Lactam Compounds
|
WO2007038466A2
(en)
*
|
2005-09-27 |
2007-04-05 |
Cobb & Company |
Treatment of bipolar disorder utilizing anti-fungal compositions
|
JP5292278B2
(en)
|
2006-04-04 |
2013-09-18 |
サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック(セーエヌエルエス) |
Method for producing bacteriophage composition and method in the field of phage therapy
|
US20110104100A1
(en)
*
|
2007-10-04 |
2011-05-05 |
Medistem Laboratories, Inc. |
Compositions and methods of stem cell therapy for autism
|
PT2254591T
(en)
*
|
2008-02-08 |
2017-11-10 |
Prothera Inc |
Inhibition and treatment of gastrointestinal biofilms
|
JP2012525427A
(en)
*
|
2009-04-29 |
2012-10-22 |
レクサン ファーマシューティカルズ インコーポレイテッド |
Clavulanate formulation for neuroprotection and treatment of neurodegenerative diseases
|
US20110091431A1
(en)
*
|
2009-10-09 |
2011-04-21 |
Prothera, Inc. |
Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
|
EP2531589B1
(en)
|
2010-02-01 |
2017-04-05 |
MikrobEX |
Bacteriotherapy for Clostridium difficile colitis
|
US9707207B2
(en)
|
2010-05-26 |
2017-07-18 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Method for diagnosing, preventing, and treating neurological diseases
|
EP2600877A4
(en)
|
2010-08-04 |
2014-05-07 |
Borody Thomas J |
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
|
ES2662412T3
(en)
*
|
2010-10-07 |
2018-04-06 |
California Institute Of Technology |
Probiotic therapies for autism
|
EP2683390B1
(en)
|
2011-03-09 |
2017-05-03 |
Regents Of The University Of Minnesota |
Compositions and methods for transplantation of colon microbiota
|
US20120276056A1
(en)
*
|
2011-04-26 |
2012-11-01 |
Wieslaw Janusz Bochenek |
Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
|
GB201112091D0
(en)
|
2011-07-14 |
2011-08-31 |
Gt Biolog Ltd |
Bacterial strains isolated from pigs
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
WO2013130773A2
(en)
|
2012-02-29 |
2013-09-06 |
Ethicon Endo-Surgery, Inc. |
Compositions of microbiota and methods related thereto
|
US10039777B2
(en)
*
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US9719144B2
(en)
|
2012-05-25 |
2017-08-01 |
Arizona Board Of Regents |
Microbiome markers and therapies for autism spectrum disorders
|
EP2890808A4
(en)
|
2012-08-29 |
2016-09-28 |
California Inst Of Techn |
Diagnosis and treatment of autism spectrum disorder
|
US8906668B2
(en)
|
2012-11-23 |
2014-12-09 |
Seres Health, Inc. |
Synergistic bacterial compositions and methods of production and use thereof
|
WO2014121304A1
(en)
*
|
2013-02-04 |
2014-08-07 |
Seres Health, Inc. |
Compositions and methods
|
CA2899925A1
(en)
*
|
2013-02-04 |
2014-08-07 |
Seres Therapeutics, Inc. |
Compositions and methods for inhibition of pathogenic bacterial growth
|
WO2014145958A2
(en)
|
2013-03-15 |
2014-09-18 |
Seres Health, Inc. |
Network-based microbial compositions and methods
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
US20160089363A1
(en)
*
|
2013-04-30 |
2016-03-31 |
Thomas Julius Borody |
Compositions and methods for treating microbiota-related psychotropic conditions and diseases
|
EP2799063A1
(en)
|
2013-04-30 |
2014-11-05 |
Ferring B.V. |
Bacteriophage therapy
|
EP4234011A3
(en)
|
2013-06-05 |
2023-09-20 |
Rebiotix, Inc. |
Microbiota restoration therapy (mrt), compositions and methods of manufacture
|
US9694039B2
(en)
|
2013-06-05 |
2017-07-04 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT), compositions and methods of manufacture
|
US9511099B2
(en)
|
2013-06-05 |
2016-12-06 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT), compositions and methods of manufacture
|
US9511100B2
(en)
|
2013-06-05 |
2016-12-06 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT), compositions and methods of manufacture
|
US10383901B2
(en)
|
2013-06-05 |
2019-08-20 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT), compositions and methods of manufacture
|
US9782445B2
(en)
|
2013-06-05 |
2017-10-10 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT), compositions and methods of manufacture
|
MX367109B
(en)
|
2013-11-25 |
2019-08-05 |
Seres Therapeutics Inc |
Synergistic bacterial compositions and methods of production and use thereof.
|
EP3082431A4
(en)
|
2013-12-16 |
2017-11-15 |
Seres Therapeutics, Inc. |
Bacterial compositions and methods of use thereof for treatment of immune system disorders
|
FI127671B
(en)
*
|
2014-05-28 |
2018-11-30 |
Filip Scheperjans |
Method for diagnostics of Parkinson’s disease
|
WO2016044578A1
(en)
*
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Antifungal therapy for the treatment of hirschsprung-associated enterocolitis
|
AU2015339290B8
(en)
*
|
2014-10-30 |
2021-08-26 |
California Institute Of Technology |
Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
|
EA201790811A1
(en)
|
2014-10-30 |
2017-11-30 |
Калифорния Инститьют Оф Текнолоджи |
COMPOSITIONS CONTAINING BACTERIA AND METHODS TO IMPROVE BEHAVIOR TYPES IN DISORDERS OF NEUROLOGICAL DEVELOPMENT
|
CN108064132A
(en)
|
2014-10-31 |
2018-05-22 |
霍勒拜欧姆公司 |
The method and composition related with the antimicrobial treatments of illness and diagnosis
|
EP3065748B1
(en)
|
2014-12-23 |
2017-11-22 |
4D Pharma Research Limited |
A bacteroides thetaiotaomicron strain and its use in reducing inflammation
|
PT3193901T
(en)
|
2014-12-23 |
2018-06-29 |
4D Pharma Res Ltd |
Pirin polypeptide and immune modulation
|
MX2017014488A
(en)
|
2015-05-14 |
2018-06-11 |
Crestovo Holdings Llc |
Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them.
|
CA2986485A1
(en)
|
2015-05-22 |
2016-12-01 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods for treating autism spectrum disorder and associated symptoms
|
US10828340B2
(en)
|
2015-06-09 |
2020-11-10 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT) compositions and methods of manufacture
|
US10799539B2
(en)
|
2015-06-09 |
2020-10-13 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT) compositions and methods of manufacture
|
US10905726B2
(en)
|
2015-06-09 |
2021-02-02 |
Rebiotix, Inc. |
Microbiota restoration therapy (MRT) compositions and methods of manufacture
|
KR102066242B1
(en)
|
2015-06-09 |
2020-01-14 |
리바이오틱스, 인코퍼레이티드 |
Microbial Restoration Therapy (MRT) Compositions and Methods of Preparation
|
MA41060B1
(en)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
HUE046770T2
(en)
|
2015-06-15 |
2020-03-30 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
MA41010B1
(en)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
ES2753779T3
(en)
|
2015-06-15 |
2020-04-14 |
4D Pharma Res Ltd |
Blautia stercosis and wexlerae for use in the treatment of inflammatory and autoimmune diseases
|
PE20180267A1
(en)
|
2015-06-15 |
2018-02-06 |
4D Pharma Res Ltd |
COMPOSITIONS INCLUDING BACTERIAL STRAINS
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
ES2662617T3
(en)
|
2015-11-20 |
2018-04-09 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
GB201520631D0
(en)
|
2015-11-23 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
GB201520638D0
(en)
|
2015-11-23 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
CN105603066B
(en)
*
|
2016-01-13 |
2020-07-14 |
金锋 |
Intestinal microbial marker of mental disorder and application thereof
|
AU2017226831B2
(en)
|
2016-03-04 |
2018-10-04 |
4D Pharma Plc |
Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
JP7216998B2
(en)
*
|
2016-03-14 |
2023-02-02 |
ホロバイオーム, インコーポレイテッド |
Modification of the Gut Microbiome to Treat Central Nervous System Psychiatric Disorders or Diseases
|
EP3465212A4
(en)
|
2016-05-23 |
2020-01-08 |
California Institute of Technology |
Regulate gut microbiota to treat neurodegenerative disorders
|
US20170360848A1
(en)
|
2016-06-15 |
2017-12-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods for treating autism spectrum disorder and associated symptoms
|
US10849936B2
(en)
|
2016-07-01 |
2020-12-01 |
Regents Of The University Of Minnesota |
Compositions and methods for C. difficile treatment
|
TW201821093A
(en)
|
2016-07-13 |
2018-06-16 |
英商4D製藥有限公司 |
Compositions comprising bacterial strains
|
US20180036352A1
(en)
|
2016-08-03 |
2018-02-08 |
Crestovo Holdings Llc |
Methods for treating ulcerative colitis
|
US10092601B2
(en)
|
2016-10-11 |
2018-10-09 |
Crestovo Holdings Llc |
Compositions and methods for treating multiple sclerosis and related disorders
|
US11026978B2
(en)
|
2016-10-11 |
2021-06-08 |
Finch Therapeutics Holdings Llc |
Compositions and methods for treating multiple sclerosis and related disorders
|
WO2018071536A1
(en)
|
2016-10-11 |
2018-04-19 |
Crestovo Holdings Llc |
Compositions and methods for treating primary sclerosing cholangitis and related disorders
|
IT201600109507A1
(en)
*
|
2016-10-28 |
2018-04-28 |
Probiotical Spa |
COMPOSITION FOR THE PREVENTIVE OR CURATIVE TREATMENT OF LIVER DISORDERS
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
EP3565533A4
(en)
*
|
2017-01-05 |
2021-02-17 |
The University of Chicago |
Inhibition of enteric infection through the modulation of microbiota
|
WO2018187464A1
(en)
|
2017-04-05 |
2018-10-11 |
Crestovo Holdings Llc |
Compositions and methods for treating diverticulitis and related disorders
|
US11433102B2
(en)
|
2017-04-05 |
2022-09-06 |
Finch Therapeutics Holdings Llc |
Compositions and methods for treating Parkinson's disease (PD) and related disorders
|
CA3097521C
(en)
|
2017-05-15 |
2023-10-17 |
Axial Biotherapeutics, Inc. |
Inhibitors of microbially induced amyloid
|
TW201907929A
(en)
|
2017-05-22 |
2019-03-01 |
英商4D製藥研究有限公司 |
a composition comprising a bacterial strain
|
EP3630942B1
(en)
|
2017-05-24 |
2022-11-30 |
4D Pharma Research Limited |
Compositions comprising bacterial strain
|
CA3064773A1
(en)
|
2017-05-26 |
2018-11-29 |
Crestovo Holdings Llc |
Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
|
EP3638271B1
(en)
|
2017-06-14 |
2020-10-14 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
TW201919668A
(en)
|
2017-06-14 |
2019-06-01 |
英商4D製藥研究有限公司 |
Compositions comprising bacterial strains
|
WO2019032573A1
(en)
|
2017-08-07 |
2019-02-14 |
Finch Therapeutics, Inc. |
Compositions and methods for maintaining and restoring a healthy gut barrier
|
GB201712733D0
(en)
|
2017-08-08 |
2017-09-20 |
Snipr Tech Ltd |
Methods & cells
|
KR20200040277A
(en)
|
2017-08-14 |
2020-04-17 |
세레스 테라퓨틱스, 인코포레이티드 |
Composition and method for treatment of cholestatic disease
|
US20200138794A1
(en)
*
|
2017-08-15 |
2020-05-07 |
Thomas Julius Borody |
Novel parasite therapy
|
CA3073838A1
(en)
|
2017-08-30 |
2019-03-07 |
Pendulum Therapeutics, Inc. |
Methods and compositions for treatment of microbiome-associated disorders
|
US11166990B2
(en)
|
2018-07-13 |
2021-11-09 |
Finch Therapeutics Holdings Llc |
Methods and compositions for treating ulcerative colitis
|
AU2019351017A1
(en)
|
2018-09-27 |
2021-04-29 |
Finch Therapeutics Holdings Llc. |
Compositions and methods for treating epilepsy and related disorders
|
CN109536399B
(en)
*
|
2018-10-16 |
2021-05-14 |
北京泛球生物科技有限公司 |
High-throughput screening method for virginiamycin high-producing strains
|
GB201901099D0
(en)
|
2019-01-27 |
2019-03-13 |
Snipr Biome Aps |
Methods, uses and compositions
|
EP3993815A2
(en)
*
|
2019-07-05 |
2022-05-11 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
WO2024003301A1
(en)
|
2022-06-29 |
2024-01-04 |
Snipr Biome Aps |
Targeting e coli cells
|